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In the last 30 years, there has been an explosion in facilities for the diagnosis and treatment of the
obstructive sleep apnoea/hypopnoea syndrome (OSAHS) as well as a rapid advancement in the under-
standing of its consequences. In the general population, the prevalence of OSAHS is approximately 3–7%
in adult men and 2–5% in adult women. OSAHS has been recognised as an independent risk factor for
disorders such as hypertension, cardiovascular disease and sleepiness-related accidents. Currently, it is
considered to be a systemic disease. This review provides a general overview of OSAHS: its epidemiology,
pathophysiology, clinical features, diagnosis and treatment, as well as its consequences for public health.
Crown Copyright  2009 Published by Elsevier Ltd. All rights reserved.Educational aims
 To outline the pathophysiology, epidemiology and clinical pre-
sentation of the obstructive sleep apnoea/hypopnoea syndrome.
 To outline the investigation of OSAHS and the potential difﬁcul-
ties in its diagnosis.
 To outline the management of OSAHS and associated potential
problems.1. Introduction
The obstructive sleep apnoea/hypopnoea syndrome (OSAHS)
affects approximately 2–4% of the middle-aged population and is
deﬁned on the basis of symptoms of daytime sleepiness and objective
measuresofdisorderedbreathingduringsleep.OSAHS is characterised
by obstruction of the upper airway during sleep, resulting in repetitive
breathing pauses accompanied by oxygen desaturation and arousal
from sleep. This results in diurnal sleepiness and can lead to cognitive
impairment and cardiovascular morbidity. The clinical presentation
and diagnostic criteria of abnormal breathing in sleep are different for
adult andpaediatric cases.1,2 This reviewwill focus onOSAHS inadults.
2. Pathophysiology of the obstructive sleep apnoea/
hypopnoea syndrome (OSAHS)
OSAHS is characterised by episodes of pharyngeal obstruction
which are termed apnoeas if complete and hypopnoeas if partial.009 Published by Elsevier Ltd. AllThe term apnoea is deﬁned, as a cessation of airﬂow for at least 10 s.
Apnoeas/hypopnoeas are often, but not always, associated with an
electroencephalographic arousal at their termination and with
a drop in oxygen saturation.2 Controversy remains regarding
a standardised deﬁnition of hypopnoea, but the deﬁnition adopted
by the American Academy of Sleep Medicine (AASM) is a 50%
reduction in thoraco-abdominal movement for at least 10 s from
the preceding stable baseline when asleep.2
Apnoeas and hypopnoeas may occur at sleep onset or during
rapid eye movement (REM) sleep in healthy individuals. Such
events are not repetitive; airﬂow cessation is less than 10 s and is
not usually accompanied by arousals, hypoxemia or an increased in
arterial PaCO2.
The pharynx is the site of UA obstruction during sleep in
patients with OSAHS. During inspiration, the size of the pharyngeal
lumen depends on the balance between narrowing forces resulting
from intrapharyngeal suction pressure and dilating forces gener-
ated principally by pharyngeal muscles. Patients with OSA
commonly have anatomical abnormalities of the UA when awake.3
The sites of UA narrowing can be broadly classiﬁed into three
regions: the retropalatal region, the retroglossal region and the
hypopharyngeal region. UA occlusion is the result of an interaction
between multiple anatomic and physiological abnormalities which
involve a small, highly compliant pharynx, central breathing
instability leading to reduced ventilatory motor output to UA
dilators and collapsing transmural pressure. The increase in air
velocity resulting from inspiratory narrowing during sleep is
thought to cause decreased intraluminal pressure according to the
Bernoulli principle causing greater collapse of the UA.3 Extra-
luminal pressures are also thought to inﬂuence UA patency
including passive gravitational forces generated by craniofacialrights reserved.
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loss of caudal traction on UA structures during sleep, as lung
volume is reduced due to the displacement of the diaphragm and
thorax toward the head, further increases UA resistance.3 Surface
mucosal factors are also thought to inﬂuence airway patency
especially in subjects with a lot of mucosal inﬂammation from
repeated trauma.3
3. Epidemiology of OSAHS
Large-scale epidemiological studies have attempted to address
questions on the incidence and prevalence of OSAHS.5 Differences
in sampling methods, techniques used for monitoring sleep and
breathing and variability in deﬁnitions can alter disease prevalence.
The prevalence of OSAHS is approximately 3–7% for adult men and
2–5% for adult women in the general population.5 The prevalence is
higher in different population subsets, including overweight or
obese people, those of a minority race, and older individuals.
Minimally symptomatic or asymptomatic sleep apnoea is estimated
to occur in one of ﬁve adults and is rarely recognised.6
4. Risk factors for OSAHS
4.1. Age
The prevalence of OSAHS increases with age 5–7 and reaches
a plateau after the age of 60 years. Mechanisms proposed for the
age-related increase in prevalence include increased deposition of
fat in the parapharyngeal area, lengthening of the soft palate and
changes in structures surrounding the pharynx.8
4.2. Obesity
The association between obesity and OSA has been noted in
many studies.4–6,9 Morbid obesity deﬁned as a body mass index
(BMI) of >30 kg/m2, is present in 60–90% of patients with OSAHS.
Central obesity characterised by a high waist:hip ratio or increased
neck circumference is better correlated with OSAHS even in those
with a normal BMI.4 Fat distribution around the neck results in
increased extraluminal pressure andmay affect the geometry of the
airway making collapse more likely.4 Data suggest that weight gain
has a greater effect on OSA than an equivalent weight loss.10 There
is evidence of a signiﬁcant correlation between metabolic
syndrome (central obesity, insulin resistance, impaired glucose
tolerance, dyslipidaemia, and hypertension) and OSAHS.11 Sleep
deprivation and poor sleep quality as consequences of OSAHS can
lead to changes in appetite.4,9 Obesity per se is an inﬂammatory
state and its metabolic consequences may affect ventilatory
control.4,9
4.3. Men, menopause and pregnancy
OSAHS is more common in men.5,6,12 The male predisposition
for the disorder has been attributed to differences in anatomical
and functional properties of the UA, differences in craniofacial
morphology and fat deposition and different ventilatory responses
to arousals from sleep.12 Women with sleep apnoea often do not
report loud snoring, gasping and witnessed apnoeas, but maymore
frequently report symptoms of fatigue and lack of energy. Health
care providers should have a lower index of suspicion for consid-
ering OSAHS in women5 and there may be a non-response of the
bed partner to the symptoms of obstructive breathing during sleep.
Women tend to have a lower AHI in non-rapid eyemovement (non-
REM) sleep but have a similar AHI in REM sleep to men.12Hormonal inﬂuences also have an important role in the patho-
genesis of OSAHS. The disease prevalence is higher in post- versus
pre-menopausal women and hormone replacement therapy has
been associated with a lower prevalence.13 Exogenous androgen
therapy in men and women can aggravate OSAHS severity14 and
women with polycystic ovary syndrome15 have a high prevalence
of OSAHS.
Pregnancy is associated with a higher prevalence of sleep
apnoea, particularly during the third trimester. Gestational weight
gain, decrease in pharyngeal luminal size and alterations in
pulmonary physiology are likely to predispose to sleep disordered
breathing.12 However, some physiologic changes that accompany
pregnancy, like higher progesterone levels and a decrease in sleep
time in the supine position may protect against OSA. OSA during
pregnancy may lead to intrauterine growth retardation, pre-
eclampsia, lower Apgar scores and birth weight.16
4.4. Race
OSAHS prevalence is as high or higher in African-Americans and
in Hispanics compared with Caucasians.5,6,17 For a given age, sex,
and BMI, Asians have greater disease severity than whites, despite
their lesser degrees of obesity, probably due to differences in
craniofacial features, such as a more crowded UA, relative retro-
gnathia and a shorter cranial base.17
4.5. Craniofacial abnormalities
OSAHS is associated with craniofacial abnormalities such as
retrognathia, tonsillar hypertrophy, enlarged tongue or soft palate,
inferiorly positioned hyoid bone, maxillary and mandibular retro-
positions. Jaw abnormalities are important in thin OSAHS
patients.18 First-degree relatives of OSAS patients are more likely to
be at risk compared with the relatives of people without the
disorder. Genetic determinants of cephalometric parameters,
obesity and regional fat distribution are also relevant. It is likely
that OSAHS is a polygenic disorder with multifactorial genetic
inﬂuence.19 Certain congenital conditions such as Marfan’s, Down’s
and the Pierre–Robin syndromes predispose to the development of
OSAHS.20
4.6. Lifestyle factors
Smoking is associated with a higher prevalence of snoring and
OSAHS and passive smoking has been linked with habitual
snoring.21 Alcohol can increase UA collapsibility by reducing the
genioglossus muscle activity, prolonging apnoea duration and
exacerbating OSAHS.22
4.7. Other conditions
Acquired conditions such as acromegaly and hypothyroidism
are also associated with OSAHS.20,23 Sedative use, sleep deprivation
and supine posture can all exacerbate sleep apnoea. Reduced
nasal patency, due to congestion or anatomical defects as well as
respiratory allergies can also contribute to OSAHS.18
5. Clinical features of OSAHS
OSAHS symptoms can be divided into those manifesting during
sleep and those present during wakefulness (Table 1).
Patients with OSAHS most commonly complain of excessive
daytime sleepiness (EDS). This may range from subtle to severe.
However, EDS is not present in all patients with OSAHS. A recent
multicenter cohort study concluded that apnoea and sleep
Table 1
Symptoms of the obstructive sleep apnoea/hypopnoea syndrome.
During sleep When awake
Nonrestorative sleep Daytime sleepiness
Witnessed apnoeas by bed partner Lack of concentration
Awakening with choking Cognitive deﬁcits
Nocturnal restlessness Changes in mood
Vivid, strange, or threatening dreams Morning headaches
Gastroesophageal reﬂux Dry mouth





Clinical features of OSAHS.
Obesity (particularly central, BMI> 28 kg/m)
Large neck circumference (>40 cm)
Narrow mandible, narrow maxilla
Retrognathia
Dental malocclusion, overjet
Nasal problems (i.e. deviated nasal septum)
High and narrow hard palate
Elongated and low-lying uvula
Enlarged tonsils and adenoids
Macroglossia
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patients with EDS were characterised by longer sleep duration,
increased slow wave sleep and sleep fragmentation.24 So the
approach to a sleepy patient presenting with symptoms of sleep
apnoea should not exclude consideration and assessment of
metabolic status, the presence of depression or other possible
causes of EDS (Table 2).25
Nocturnal symptoms of OSAHS are sometimes apparent to the
patient but generally, are reported by a bed partner. The most
common include snoring, snorting, choking attacks terminating
a snore and witnessed apnoeas. Although an absence of snoring
does not exclude the diagnosis of OSAHS, virtually all patients
snore. Apnoeic episodes are reported by about 75% of bed part-
ners.26 Bed partners will generally report a sudden cessation of
snoring followed by a loud snort and a resumption of snoring. Some
patients will awake after such a sequence; however, most are
unaware of their disordered breathing.27 Those who are aware of
frequent events leading to awakening can try to delay and prevent
themselves from falling asleep, thus presenting with a ‘paradoxical’
insomnia. A number of clinical features are associated with OSAHS
(Table 3), but the predictive value of any single one is limited in
conﬁrming the diagnosis.26
History and clinical examination alone (including blood pres-
sure and BMI) can predict the presence of OSAHS in only 50% of
patients attending a sleep disorders clinic.26 Deﬁnitive diagnosis
requires overnight investigation of breathing patterns (Table 4).
6. Morbidity and mortality associated with OSAHS
Untreated OSAHS can contribute to the development or
progression of other disorders. Patients with OSAHS have higher
mortality, use more medical resources and have greater medical
disability.28,29
6.1. Systemic hypertension
OSAHS is a cause of systemic hypertension.30 The mechanisms
contributing to this include tonic elevation of sympathetic neuralTable 2
Differential diagnosis of excessive daytime sleepiness.
Obstructive sleep apnoea/hypopnoea (OSAHS)
Upper airway resistance syndrome (UARS)
Narcolepsy – Central nervous system hypersomnolence
Periodic leg movements during sleep
Insufﬁcient sleep syndrome
Alcohol, medication and drug use
Schedule disorders/shift work
Chronic pain and discomfort
Delayed sleep phase syndrome
Severe lung disease
Neurologic – Neuromuscular diseaseactivity by the augmentation of peripheral chemoreﬂex sensitivity
(intermittent hypoxia at night), direct effects on sites of central
sympathetic regulation and the disturbance of nocturnal renin and
aldosterone levels due to severe sleep fragmentation.31
6.2. Cardiac disease, dysrhythmias
OSAHS is associated with the development of ischemic heart
disease.32 Hypoxia, hypercapnia and pressure changes accompa-
nying obstructive apnoeic events (reduction in intra-thoracic
pressure) may stimulate the release of vasoactive substances. The
reduction in intra-thoracic pressure increases the left ventricular
transmural pressure and left ventricular afterload. Venous return is
enhanced, resulting in right ventricular distension and leftward
shift of the inter-ventricular septum. Cardiac function is compro-
mised by a combination of diminished left ventricular pre-load and
augmented left ventricular afterload, which together reduces the
stroke volume. Chronic intermittent hypoxia can induce oxidative
stress and an inﬂammatory state and thus contribute to the
development of atherosclerosis in OSAHS patients.32 OSAHS also
leads to abnormalities of coagulation (hypercoagulability) and
excessive platelet activation.32
Nocturnal disturbances in cardiac rhythm (heart block, atrial
ﬁbrillation, ventricular ectopy) have been reported in patients with
OSAHS,32 but the most common arrhythmias are severe sinus
bradycardia and atrioventricular block, as a response to apnoea and
hypoxia.32 OSAHS may also be involved in the pathogenesis of
nocturnal sudden death.32
6.3. Cerebrovascular disease
Patients with OSAHS appear to be at increased risk of having
a stroke.33 The negative intra-thoracic pressure generated during
an apnoea decreases cerebral blood ﬂow predisposing to ischemic
changes in some patients. Other risk factors for stroke, such as
systemic hypertension, heart disease, impaired vascular endothe-
lial function and proinﬂammatory states may be exacerbated by
OSAHS. Some studies show no increase in OSAHS in those with
TIA,34 whilst others show a high prevalence of OSAHS in those with
stroke.33 There are insufﬁcient data to support that treatment ofTable 4
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leads to improvement in quality of life.35
6.4. Pulmonary hypertension – Cor pulmonale
OSAHS may contribute to the development of pulmonary
hypertension (PH). The apnoea-induced hypoxia appears to be the
most important determinant of PH. Development of right ventric-
ular hypertrophy is related to the severity of OSA, but development
of right heart failure requires additional alterations in daytime
respiratory function and is associated with lung disease or morbid
obesity.36
6.5. Co-existent lung disease
The combination of chronic obstructive pulmonary disease
(COPD) and OSAHS has been termed as ‘‘overlap syndrome’’.37
Quality of sleep in COPD is inﬂuenced by the presence of OSAHS but
not by the severity of airway obstruction. Patients with overlap
syndrome, are more sleepy, have lower total sleep time and higher
AHI compared with those who have COPD alone and are at greater
risk of developing PH, right heart failure and hypercapnia even
though their obstructive defect may not be severe.37 Nocturnal
asthma may also be worsened by sleep apnoea.38
6.6. Neuropsychological impairment-quality of life
OSAHS leads to neuropsychological impairment that includes
deﬁcits in attention, concentration, vigilance, manual dexterity,
visuomotor skills, memory, verbal ﬂuency and executive function.27
Sleepiness, depression, fatigue and obesity have an important
impact on the person’s quality of life.39 Patients report problems
with relationships and sex, as well as concerns about poor memory
and a fear of dying.39
6.7. Accidents
One of the most important complications and the onewhich has
the greatest impact from the public health perspective is driving
accidents.40 Vigilance testing and driving simulators in studies
assessing driving performance in OSAHS patients reveal that
performance is markedly reduced and the impairment is not just
limited to periods when patients actually fall asleep but also when
they are awake due to reduced vigilance. Motor vehicle crashes
correlate with the degree of sleepiness and not the AHI.40 There is
also evidence that OSAHS patients have an increased risk of work
place accidents.41
6.8. OSAHS as a systemic disease
OSAHS patients have increased levels of certain biomarkers
relating to metabolic, cardiovascular and other systemic conse-
quences.11,42 The levels of some biomarkers decrease with contin-
uous positive airway pressure (CPAP) treatment and this
observation indicates that OSAHS is more than a local abnormality
and should be considered a systemic disease.11,42
7. Diagnosis of OSAHS
A deﬁnitive diagnosis of OSAHS requires objective recording and
measurement of sleep and breathing during the night in addition to
a measure of daytime sleepiness (objective or subjective) and other
symptoms.7.1. Recording and measurement of sleep and breathing
during the night
Themethodmost widely used, andwhich is considered by some
to be the ‘gold standard’ for diagnosis of OSAHS, is overnight pol-
ysomnography (PSG).43 Most PSG studies monitor the following:
nasal and/or oral airﬂow; thoraco-abdominal movement; snoring;
electroencephalogram (EEG); electro-oculogram (EOG); electro-
myogram (EMG); and oxygen saturation. Also recording of any
abnormal movements using video may help identify changes in
airﬂow or desaturations. Signal collection and interpretation are
usually computerised, but manual scoring of the trace should still
be performed using guidelines for interpretation of the EEG2,44 for
scoring of respiratory and other events. Night to night variability
makes it possible for a single study to underestimate the severity of
OSAHS. A negative PSG should be viewed with scepticism if the
clinical suspicion of OSAHS is high.45
Split-night studies46 in which the ﬁrst half of the study night is
used for diagnosis and the second half to monitor treatment
response using continuous positive airway pressure are also used.
Split-night studies are considered accurate and cost effective when
criteria for conducting them are met.46
A more recent introduction to the assessment of sleep apnoea
has been cardiorespiratory monitoring alone. This involves the
measurement of airﬂow, respiratory effort, oxygen saturation and
heart rate, but not EEG. The great advantages of these systems are
price and portability and the ability of patients to monitor them-
selves at home.47 Overnight oximetry is sometimes used as
a screening test for identifying patients who are at risk of having
signiﬁcant OSAHS but should never be seen as a substitute for in-
lab PSG or home cardiorespiratory monitoring. There are severe
limitations of this technique, especially the inability to detect
apnoeas or hypopnoeas not associated with oxygen desaturation.
Furthermore, nocturnal oxygen desaturation may be related to
sleep hypoventilation without UA obstruction e.g. COPD, severe
kyphoscoliosis, muscular dystrophy.43,47
7.2. Assessing daytime sleepiness
Sleepiness is difﬁcult to deﬁne.48 It can be classiﬁed using
behavioural measures, performance tests, self-evaluation by rating
scales or direct electrophysiological measures. The most widely
used and best-validated scale for assessing daytime sleepiness is
the Epworth Sleepiness Scale (ESS).49 An ESS of >11 out of 24
(maximum score) is generally indicative of abnormal levels of
daytime sleepiness, irrespective of age. The ESS aims at measuring
the general level of daytime sleepiness as a stable individual
characteristic and has satisfactory test–retest reliability.49
8. Treatment of OSAHS
Until 1981, when Sullivan et al.50 introduced CPAP as a treat-
ment for OSAHS, tracheostomy51 and weight loss4 were the only
established beneﬁcial remedies. A number of modalities have been
employed in the treatment of OSAHS, each with inherent
limitations.52,53
8.1. Conservative measures
Lifestyle modiﬁcation is probably the simplest, cheapest and
least effective method for the long-term treatment of OSAHS.
This includes advice about weight loss, exercise, and sleep
hygiene, avoidance of smoking and alcohol and sedative medi-
cations. Weight loss can lead to clinically signiﬁcant improve-
ment.4 Sleep position has also been looked at in terms of
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adjunct to weight loss and to alter sleep structure. Sleep hygiene
advice includes measures to improve the sleep environment,
avoid stimulants before bedtime, avoid daytime naps, sleep
deprivation etc.52 Avoiding excessive alcohol in the evenings has
been shown to be important,22 whilst smokers have higher risk
of snoring and OSA.21 There are very few randomised controlled
trials looking at the effects of these lifestyle modiﬁcations in the
context of OSAHS but, as they are non-invasive, they continue to
be recommended.8.2. Continuous positive airways pressure (CPAP)
CPAP treatment is considered the treatment of choice in patients
with moderate-to-severe OSAHS.53,54 Patients with mild OSAHS or
those with limited symptoms but comorbid conditions (e.g.
ischemic heart disease) or who perform mission critical work (e.g.
airline pilot, bus driver) must also be offered treatment.54
CPAP acts as a pneumatic splint, delivering a predetermined
constant pressure during both inspiration and exhalation, pre-
venting collapse of the pharyngeal airway by elevating the
pressure in the oropharyngeal airway and reversing the trans-
mural pressure gradient across the pharyngeal airway. The
optimal pressure (cmH2O) is titrated to reduce the AHI to less
than ﬁve ideally. There are various mask sizes and types avail-
able. CPAP results in signiﬁcant improvements in objective and
subjective sleepiness, measures of oxygenation, mean arterial
blood pressure and pulmonary haemodynamics as well as in
health status and the mental health.52–54 CPAP treatment reduces
biomarkers that reﬂect proatherogenic inﬂammation, improves
cardiovascular mortality and morbidity, reduces prevalent
dysrhythmias and improves left ventricular function.32 CPAP
treatment effectiveness is limited by variable adherence to
therapy. One can determine compliance using a patient ques-
tionnaire, by electrically timing how long the device is on each
night or by electronically recording how long the patient is
actually breathing through it each night.54,55 When adherence is
deﬁned as greater than 4 h per night, 46–83% of patients with
obstructive sleep apnoea have been reported to be nonadherent
to treatment.55 Speciﬁc predictors of CPAP adherence have not
been consistently isolated. Symptomatic severity as measured by
ESS, patient characteristics, such as claustrophobia, other
psychological and social variables, increased nasal resistance,
partner interaction and the method of CPAP initiation inﬂuence
adherence.55
CPAP is not without problems and common side-effects can
include: nasal congestion, nasal dryness, epistaxis, skin abrasions,
partner intolerance and inconvenience.54,55 Ways to improve
adherence to therapy are humidiﬁcation, behavioural interven-
tions, patient-centered mask and device selection, patient educa-
tion, early intervention and support of side-effects.558.3. Oral appliances (OA)
Today, the most commonly used oral appliances are the
mandibular advancement devices (MADs) which reposition the
mandible and the tongue in a forward position during sleep.56
Excessive salivation, tooth discomfort and dental defects are some
of the reported side-effects. AlthoughMADs are effective at treating
OSAHS, their beneﬁt appears to be less than that of CPAP.53 MADs
should be used in the treatment of simple snoring or mild sleep
apnoea, being reserved for the treatment of moderate or severe
sleep apnoea only in instances where CPAP therapy had failed or
has been declined by the patient.53,568.4. Surgery
Surgery for sleep apnoea is a complex and controversial ﬁeld
and encompasses procedures carried out by surgeons attached to
the subspecialties of otolaryngology, maxillofacial surgery and
specialised surgery of the gastrointestinal system (bariatric
surgery).57,58 The aim of surgical treatment is to bypass or remove
the site of UA obstruction. Some surgeons hold the tracheostomy to
be the ‘gold standard’ for treating OSAHS, as it conveniently
bypasses the upper respiratory tract where the problem resides;
but this solution comes with its fair share of comorbidities. Severe
nasal mucosal congestion may impede nasal CPAP therapy or OA
therapy and speciﬁc abnormalities such as a grossly deviated nasal
septum or nasal polyposis should be treated in selected patients.57
8.5. Pharmacotherapy
There is currently little evidence for any of the drugs trialled in
the management of OSAHS to be effective.59 The effectiveness of
modaﬁnil, a central nervous system stimulant, for the treatment of
residual sleepiness has been demonstrated, but there are conﬂict-
ing data regarding the impact of modaﬁnil therapy on CPAP use.60
9. Concluding remarks
OSAHS is an important condition within our community with
the potential of being a signiﬁcant health burden. OSAHS has been
recognised as an independent risk factor for disorders such as
hypertension, cardiovascular disease, and abnormalities in glucose
metabolism, depression and sleepiness-related accidents. It can be
easily diagnosed and readily, although not always easily, treated.
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Educational questions
Answer the following question:






2. OSAHS prevalence is higher:
a. in pre- versus post-menopausal women
b. in women on hormone replacement therapy
c. in exogenous androgen therapy in men
d. in people with BMI< 25 kg/m2
A. Pataka, R.L. Riha / Respiratory Medicine CME 2 (2009) 111–1171163. Which one of the following is true when making a diagnosis of
OSAHS?
a. A negative PSG means OSAHS can be safely excluded
b. Overnight oximetry can be used as a substitute for in-lab
PSG or home cardiorespiratory monitoring for all patients
c. Split-night studies are considered accurate and cost effec-
tive when criteria for conducting them are met
d. An ESS in the range of <11 out of 24 is indicative of
abnormal levels of daytime sleepiness.
4. Which of the following statements is true regarding the
treatment of OSAHS?
a. The most effective long-term treatment for patients with
mild OSAHS is exercise and sleep hygiene
b. MADs should be used routinely for treating severe sleep
apnoea
c. CPAP treatment increases biomarkers that reﬂect proa-
therogenic inﬂammation
d. CPAP treatment effectiveness is limited by variable adher-
ence to therapy.
5. Which of the following is true of OSAHS?
a. Mild OSAHS alone can lead to the development of right
heart failure
b. OSAHS can contribute to the development of
atherosclerosis
c. History and clinical examination alone can predict the
presence of OSAHS in 90% of patients attending a sleep
disorders clinic
d. All patients with OSAHS complain of excessive daytime
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